Clinical Trial Update: A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa [Phase 2]

View source ↗

Summary

A Phase 2 pilot trial of HP802-247 for Dystrophic Epidermolysis Bullosa has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dystrophic Epidermolysis Bullosa

Drugs mentioned

• hp802-247

Snippet

Sponsor: Healthpoint | Conditions: Dystrophic Epidermolysis Bullosa | Phase 2 | Status: WITHDRAWN